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Abstract
Background: Rates of retinopathy of prematurity (ROP) and 
ROP treatment vary between neonatal intensive care units 
(NICUs). Neonatal care practices, including oxygen satura-
tion (SpO2) targets and criteria for the screening and treat-
ment of ROP, are potential contributing factors to the varia-
tions. Objectives: To survey variations in SpO2 targets in 
2015 (and whether there had been recent changes) and cri-
The complete list of iNEO Investigators can be found in the online 
Supplementary Information.
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teria for ROP screening and treatment across the networks 
of the International Network for Evaluating Outcomes in 
Neonates (iNeo). Methods: Online prepiloted question-
naires on treatment practices for preterm infants were sent 
to the directors of 390 NICUs in 10 collaborating iNeo net-
works. Nine questions were asked and the results were sum-
marized and compared. Results: Overall, 329/390 (84%) 
NICUs responded, and a majority (60%) recently made 
changes in upper and lower SpO2 target limits, with the me-
dian set higher than previously by 2–3% in 8 of 10 networks. 
After the changes, fewer NICUs (15 vs. 28%) set an upper 
SpO2 target limit > 95% and fewer (3 vs. 5%) a lower limit 
< 85%. There were variations in ROP screening criteria, and 
only in the Swedish network did all NICUs follow a single 
guideline. The initial retinal examination was carried out by 
an ophthalmologist in all but 6 NICUs, and retinal photog-
raphy was used in 20% but most commonly as an adjunct 
to indirect ophthalmoscopy. Conclusions: There is consid-
erable variation in SpO2 targets and ROP screening and 
treatment criteria, both within networks and between 
countries. © 2018 S. Karger AG, Basel
Introduction
The incidence of retinopathy of prematurity (ROP) 
varies considerably among centers, both within [1, 2] and 
between countries [3]. We recently reported that, for in-
fants born between 240 to 276 weeks’ gestation, the rates 
of ROP treatment varied from 4.4 to 30.4% across 10 neo-
natal networks contributing to the International Network 
for Evaluating Outcomes in Neonates (iNeo) [4]. Differ-
ing care practices and treatment criteria are amongst the 
possible factors contributing to the observed variations.
ROP is recognized as having a multifactorial etiology, 
but the most consistent associations are lower gestational 
age (GA), smaller size for gestation, and some measure of 
oxygen exposure [5]. Both hyperoxia and hypoxia, and 
fluctuations in oxygenation, are implicated in animal 
models of oxygen-induced retinopathy and clinical ob-
servational studies [5]. Being noninvasive and simple to 
use, monitoring supplementary oxygen by means of a 
pulse oximeter measuring oxygen saturation (SpO2) has 
become routine since the 1990s [6]. Uncertainties about 
the optimal SpO2 target range in preterm infants contrib-
ute to variations in practice between neonatal intensive 
care units (NICUs) [7], whilst recent trials of SpO2 target-
ing in preterm infants [8] have resulted in many NICUs 
reappraising and changing their targets.
To identify possible contributors to the observed vari-
ation in rates of severe and treated ROP, we surveyed 
NICUs included in the iNeo dataset. We specifically 
sought information on each NICU’s current SpO2 target 
limits as well as any recent change, the criteria for screen-
ing for ROP, the personnel conducting initial retinal ex-
aminations, the use of digital photographs, and treatment 
criteria.
Methods
Online, prepiloted, anonymous questionnaires on treatment 
practices relating to extremely preterm infants under 29 weeks’ 
gestation (68 questions taking 30 min to complete) were sent to 
the neonatologist directors of 390 tertiary NICUs in 10 collaborat-
ing population-based networks: Australia/New Zealand (n = 28), 
Canada (n = 30), Finland (n = 5), Israel (n = 26), Japan (n = 204), 
Spain (n = 57), Sweden (n = 6), Switzerland (n = 12), Illinois, the 
USA (n = 18), and the region of Tuscany, Italy (n = 4). All NICUs 
are level 3 or mixed level 2 and 3 and provide specialized care for 
infants born at < 29 weeks’ gestation. In Japan, 15 of 99 tertiary 
units do not participate in the iNeo, but the survey was sent to the 
84 which do, plus 188 mixed level 2 and 3 units. The neonatologist 
respondents were instructed to provide answers reflecting their 
unit practice/protocols, based on their 2015 standards, and not 
personal preferences. No questions were mandatory, and the re-
sponse rate was monitored weekly. A reminder questionnaire was 
sent twice to nonresponding units. The survey commenced in Au-
gust 2016 and closed in December 2016. The responses were sum-
marized and compared between the networks. The 9 questions 
relevant to ROP comprised 4 domains: SpO2 (3 questions), eryth-
ropoietin use (1 question), ROP screening criteria and personnel 
conducting the examination (3 questions), and ROP treatment 
criteria and mode of treatment (2 questions) (Table 1). Survey 
questions regarding frequency included the choices: routine (90–
100%), often (50–90%), sometimes (10–49%), and rarely/never 
(0–10%). 
Data Analysis
Data are reported using descriptive statistics. The t test was 
used to compare mean percentage differences between the upper 
and lower SpO2 target limits for each network and the iNeo col-
laboration overall.
Ethics Approval 
All participating networks obtained ethics/regulatory approval 
or the equivalent from their local granting agencies as part of the 
protocol for collaborative comparisons of international health ser-
vices and practices for quality improvement in neonatal care [9]. 
Specific approval for this project was obtained from the Research 
Ethics Board at Mount Sinai Hospital, Toronto where the project 
was coordinated. The responders were asked to complete the sur-
vey only if they provided consent for data assimilation and anony-
mous reporting.
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Results
Overall, 329 of 390 (84%) NICUs responded to some 
or all of the ROP-related questions, with the response rate 
varying between 76 and 100% of the participating units in 
individual networks (median 96%).
SpO2 Targeting 
Of the NICUs that responded, 194 (60%) had recently 
changed their SpO2 targets. In 7 networks, a majority of 
NICUs made changes, in 2 networks 50% of the units made 
changes, and in Japan, a minority of units (36%) made 
changes (Fig. 1; online suppl. Fig.; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000490372). 
The most common upper SpO2 target limit prior to 
change was 92% (range 90–98%), adopted by 25% of 
NICUs overall and 43% of NICUs making a change, ex-
cluding Japan (where only 6 of 151 NICUs adopted this 
target). After the change, the upper SpO2 target limit 
was 94 or 95% (range 90–98%) in 68% of the NICUs. 
The most common lower SpO2 target limits prior to 
change were 88% (in 20% of NICUs) and 85% (in 11% 
of NICUs). After change, the lower SpO2 limit was 90% 
(34% overall and 43% of NICUs making a change). In 
all networks, the median upper SpO2 target increased 
after change, except for Japan where it remained at 95%. 
Canada and Japan were the only networks where the 
median lower SpO2 target did not increase after change, 
remaining 88% in Canada and falling from 90 to 88% in 
Japan.
After any SpO2 target change, fewer NICUs adopted 
an upper SpO2 target > 95% (15 vs. 28% before any change) 
and all but 4 of the 50 NICUs with an upper SpO2 target 
> 95% after any change were in Japan. After change, 10 
Table 1. iNeo Web survey questions on treatment practices related to ROP
1 What is the current SpO2 target range after NICU admission for preterm infants (<29 weeks’ GA) in your institution?
Lower limit Upper limit Comments
2 Did you change the SpO2 target range for preterm infants (<29 weeks’ GA) after NICU admission recently, based on recent RCTs 
(SUPPORT, BOOST, COT)?
Yes No
3 If yes, what was the prior SpO2 target range after NICU admission?
Lower limit Upper limit Comments
4 Do you generally use erythropoietin for very preterm infants?
<26 weeks’ 26–28 weeks
5 What are the criteria for routine mandatory ROP screening in your unit?
BW-based criteria GA-based criteria Other
6 Who generally conducts the initial eye examination for ROP screening in your unit?
An ophthalmologist A nonophthalmologist
7 What method is used for the initial eye examination for ROP screening in your unit?
Indirect ophthalmoscopy only Retinal photography only Both
8 What are the criteria for ROP treatment (laser ablation/intravitreal anti-VEGF) for your infants (your institution or where you 
refer them to)?
Type 1 ROP# Threshold ROP* Other
9 Do you use anti-VEGF injections for the treatment of ROP?
Yes No
iNeo, International Network for Evaluating Outcomes of Neonates; SpO2, pulse oximeter-measured oxygen saturation; NICU, neo-
natal intensive care unit; GA, gestational age; RCTs, randomized controlled trials (SUPPORT, Surfactant, Positive Pressure and Oxy-
genation Randomized Trial [13]; BOOST, Benefits of Oxygen Saturation Targeting Trials [14]; COT, Canadian Oxygen Trial [18]); ROP, 
retinopathy of prematurity; BW, birth weight; VEGF, vascular endothelial growth factor.
# Definition according to ET-ROP criteria [10]: Zone I, any stage ROP with disease; Zone I, stage 3 ROP with or without disease; 
Zone II, stage 2 or 3 ROP with disease.* Definition according to CRYO-ROP criteria [11]: at least 5 contiguous or 8 cumulative clock hours of stage 3 ROP in the presence 
of disease.
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NICUs adopted a lower target < 85% compared with 15 
NICUs before change. 
Table 2 shows the mean difference between the upper 
and lower SpO2 targets limits in 2015 and prior to any 
change, for either all NICUs in each network or only 
NICUs that changed SpO2 targets. In the Australian and 
New Zealand Neonatal Network (ANZNN) and Finland, 
the SpO2 target range was significantly narrower after 
change, both for the network overall and for those NICUs 
making a change. However, in Canada, the SpO2 target 
range was significantly narrower only in the 50% of the 
NICUs making a change. In contrast, in Japan, the target 
range was significantly wider in the 43% of NICUs mak-
ing a change. There were no other significant differences 
in SpO2 targets limits, in either individual networks or the 
iNeo overall.
ROP Screening Criteria
A majority of NICUs used screening criteria based on 
a GA and/or birth weight (BW) cut-off (only 1 was re-
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Fig. 1. Upper (a) and lower (b) oxygen saturation (SpO2) target 
limits before (left) and after (right) any changes in response to pub-
lished SpO2 targeting trials [13, 14]: all iNeo NICUs responding to 
the survey. The size of the circle corresponds to the percentage of 
units within the network, i.e., a larger circle denotes a higher per-
centage. The median value for each network is indicated with “+”; 
n, number of NICUs. ANZNN, Australian and New Zealand Neo-
natal Network; CNN, Canadian Neonatal Network; FinMBR, 
Finnish Medical Birth Register; ILNN, Illinois Neonatal Network; 
INN, Israel Neonatal Network; NRNJ, Neonatal Research Net-
work of Japan; SEN1500, Spanish Neonatal Network; SNQ, Swed-
ish Neonatal Quality Register; SwissNeoNet, Swiss Neonatal Net-
work; TuscanNN, TIN Toscane Online.
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quired) (Fig. 2), but there remained considerable varia-
tion, and only Sweden had a single guideline for all NICUs 
(< 31 weeks’ GA with no BW cut-off). The most common 
screening criterion was GA < 31 weeks’ or BW < 1,250 g. 
However, some NICUs used a GA cut-off of < 30 weeks’ 
and some a BW cut-off of < 1,000 g.
In all networks, an ophthalmologist usually completed 
the initial eye examination. In 6 NICUs (4 in the ANZNN 
and 2 in Japan), the initial examination was undertaken 
by a nonophthalmologist. Whilst most NICUs in all net-
works used indirect ophthalmoscopy for this examina-
tion, retinal photography was used in some NICUs in 
each network, most frequently together with ophthal-
moscopy (15% all NICUs). Fourteen NICUs (5%) spread 
over 6 networks used retinal photography alone for the 
initial eye examination.
ROP Treatment Criteria
There was variation in treatment criteria both within 
and between networks (Fig. 3), with most NICUs (65%) 
using early treatment (ET)-ROP type 1 disease criteria 
[10], 29% CRYO-ROP threshold criteria [11], and a few 
(6%) other criteria. Anti-VEGF (vascular endothelial 
growth factor) therapy was used in 43% of NICUs and in 
all 10 networks (range 23–81% of NICUs).
Erythropoietin Use
Erythropoietin was not used in Canada, Finland, or 
Sweden, and rarely in other networks (4–23% of NICUs), 
except for Spain (42% of NICUs) and Japan (93% of 
NICUs). These results did not differ for infants < 26 weeks’ 
and 26–28 weeks’ GA. 
Discussion
In this large international survey, we identified consid-
erable variation in SpO2 target limits for very preterm in-
fants across 329 contributing NICUs from 10 networks 
and 11 countries. A majority (60%) of NICUs made 
changes, such that the median lower and upper SpO2 tar-
get limits were set 2–3% higher than previously in 8 of the 
10 networks. ROP screening criteria varied considerably 
amongst NICUs, with Sweden being the only network 
with a single guideline followed by all NICUs. The initial 
retinal examination was carried out by an ophthalmolo-
gist in all but 6 NICUs. Retinal photography was used in 
20% of the NICUs, with 75% of these using it at the same 
time as indirect ophthalmoscopy. Treatment criteria var-
ied less than screening criteria, with all but 6% of the 
NICUs following 1/2 criteria; however, only 65% NICUs 
treated ET-ROP type 1 disease [10]. In 8 networks, eryth-
ropoietin was never or rarely used, but it was used in 43% 
of NICUs in Spain and 93% in Japan.
Table 2. Mean percentage difference between upper and lower 
SpO2 target limits in 2015 and prior to any change for each net-
work overall or NICUs that changed the SpO2 target
Network 2015 targets Prior targets p
n mean n mean
ANZNN
All units 26 4.4 27 5.2 0.007
Change units 25 4.4 25 5.2 0.007
CNN
All units 30 5.27 30 5.83 0.17
Change units 15 4.73 15 5.87 0.04
FinMBR
All units 5 5.2 5 6.6 0.04
Change units 3 4.67 3 7.0 0.01
ILNN
All units 16 6.19 16 6.88 0.18
Change units 14 6.21 14 7.0 0.17
INN
All units 26 5.58 26 5.7 0.41
Change units 19 5.47 19 5.68 0.35
NRNJ
All units 151 8.26 151 7.3 0.08
Change units 66 7.82 66 7.11 0.02
SEN1500
All units 47 4.98 47 5.32 0.15
Change units 37 5.19 37 5.62 0.12
SNQ
All units 6 4.17 6 4.33 0.27
Change units 5 4.0 5 4.2 0.17
SwissNeoNet
All units 11 7.55 11 8.0 0.33
Change units 8 7.12 8 7.75 0.31
TuscanNN
All units 4 7.5 4 6.0 0.21
Change units 2 9.5 2 6.5 0.21
iNeo Total
All units 323 6.7 323 6.5 0.28
Change units 194 6.12 194 6.23 0.31
SpO2, pulse oximeter-measured oxygen saturation; NICU, 
neonatal intensive care unit; ANZNN, Australian and New Zea-
land Neonatal Network; CNN, Canadian Neonatal Network; 
FinMBR, Finnish Medical Birth Register; ILNN, Illinois Neonatal 
Network; INN, Israel Neonatal Network; NRNJ, Neonatal Re-
search Network of Japan; SEN1500, Spanish Neonatal Network; 
SNQ, Swedish Neonatal Quality Register; SwissNeoNet, Swiss 
Neonatal Network; TuscanNN, TIN Toscane Online; iNeo, Inter-
national Network for Evaluating Outcomes of Neonates.
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Fig. 2. Retinopathy of prematurity (ROP) screening criteria. All 
numbers are the percentage of units within each network. * Indi-
cates that the screening criteria is a combination of the specified 
gestational age (GA) or a birth weight (BW) < 1,500 g; ** indicates 
that the screening criteria is a combination of the specified GA or 
a BW < 1,250 g. The category “Other” included GA < 29 weeks in 
combination with different BWs, and BW < 1,000 g with different 
combinations of GA. ANZNN, Australian and New Zealand Neo-
natal Network; CNN, Canadian Neonatal Network; FinMBR, 
Finnish Medical Birth Register; ILNN, Illinois Neonatal Network; 
INN, Israel Neonatal Network; NRNJ, Neonatal Research Net-
work of Japan; SEN1500, Spanish Neonatal Network; SNQ, Swed-
ish Neonatal Quality Register; SwissNeoNet, Swiss Neonatal Net-
work; TuscanNN, TIN Toscane Online. 
ANZNN
(n = 27)
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(n = 30)
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(n = 5)
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(n = 44)
SNQ
(n = 6)
SwissNeoNet
(n = 10)
TuscanNN
(n = 4)
100
80
60
40
20
0
Re
sp
on
de
nt
s i
n e
ac
h n
et
wo
rk,
 %
 Type 1 ROP
■ CRYO-ROP threshold
■ Other criteria
Fig. 3. Retinopathy of prematurity (ROP) treatment criteria. All 
numbers are a percentage of units within each network. # Type 1 
ROP as defined by the Early Treatment for Retinopathy of Prema-
turity Cooperative Group 2003 [10]; * threshold ROP as defined 
by the Cryotherapy for Retinopathy of Prematurity Cooperative 
Group 2001 [11]. ANZNN, Australian and New Zealand Neonatal 
Network; CNN, Canadian Neonatal Network; FinMBR, Finnish 
Medical Birth Register; ILNN, Illinois Neonatal Network; INN, 
Israel Neonatal Network; NRNJ, Neonatal Research Network of 
Japan; SEN1500, Spanish Neonatal Network; SNQ, Swedish Neo-
natal Quality Register; SwissNeoNet, Swiss Neonatal Network; 
TuscanNN, TIN Toscane Online.
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A recent survey of 200 European NICUs reported that 
81% had changed their SpO2 limits in the previous 10 
years [12], with new limits typically 3–5% higher than 
previously, and 54% of NICUs citing strong or very strong 
scientific evidence in support of these changes. Although 
we did not survey the reasons for change, it is probable 
that the 60% of NICUs that changed their SpO2 targets 
also did so in response to recent trial data and the result-
ing commentaries [13–16].
The 5 recent trials of lower (85–89%) or higher (91–
95%) SpO2 targeting in infants < 28 weeks’ gestation all 
found no differences in the primary outcome of death or 
neurodevelopmental impairment at 18–24 months of age 
[17–20]. However, 3 trials reported an increased risk of 
death at hospital discharge in infants randomized to the 
lower SpO2 target [13, 14]. A Cochrane review of all 5 tri-
als, comprising nearly 5,000 infants, confirmed an in-
creased risk of death at 18–24 months (risk ratio [RR] 
1.16; 95% confidence interval [CI] 1.03–1.31]) and severe 
necrotizing enterocolitis (RR 1.24; 95% CI 1.05–1.47) 
with the lower SpO2 target, but a decreased risk of ROP 
requiring treatment (RR 0.72; 95% CI 0.61–0.85) [8]. It is 
likely that concerns about increasing the risk of ROP is 
one reason why not all NICUs have adopted higher SpO2 
targets [21–23]. However, our survey suggests that whilst 
many NICUs did change to higher SpO2 targets, some 
with initial upper limits > 95% changed to an upper limit 
of ≤95%, most notably in Japan. In our previous report, 
we found that Japan had the highest rate of both ROP and 
ROP treatment for infants 240 to 276 weeks’ gestation [4]. 
It will be interesting to see if the altered SpO2 targets im-
pact the incidence of ROP in Japan and other countries 
over the coming years.
Japan and Canada were the only networks where the 
median lower SpO2 target did not increase after any SpO2 
target change, although in the 50% of NICUs in Canada 
that changed SpO2 targets, the median lower target in-
creased from 88 to 90%. The relative stability of the lower 
SpO2 target in Canada might be because many NICUs 
collaborated in the Canadian Oxygen Trial (COT), which 
did not find a difference in mortality between lower and 
higher SpO2 targets [18]. No NICUs in Japan were in-
volved in the recent trials, and only a minority made any 
change in SpO2 targets.
The NeOProM trials investigated the effects SpO2 tar-
get limits rather than alarm limit settings. In a prelimi-
nary study using the trial Masimo SpO2 monitor, compli-
ance with SpO2 target limits was found to be only 50% on 
average [7]. Compliance was improved when the alarm 
limits were tighter at 1% above and 1–2% below the target 
limits, and also when the SpO2 target was wider. In 8 of 
the 10 iNeo networks, the median SpO2 target range was 
narrower after change, although this was only significant 
in the ANZNN and Finland. Interestingly, Switzerland 
and the ANZNN had the lowest rates of ROP treatment 
in our previous study, but here they had respectively rela-
tively wide (7.6%) and narrow (4.4%) median target rang-
es [4]. How best to achieve compliance with target rang- 
es remains controversial, but having set alarm limits 
and feedback on compliance are likely to be important 
[24, 25].
Japan was the only network where a majority of NICUs 
(93%) treated very preterm infants with erythropoietin. 
In a meta-analysis of erythropoietin treatment to prevent 
anemia of prematurity, receipt of erythropoietin was as-
sociated with a significantly increased risk of severe ROP 
(RR 1.48; 95% CI 1.02–2.13) [26]. Japan had both the low-
est mortality and highest rate of ROP treatment in the 
iNeo [4], and any association with erythropoietin use 
would require further investigations.
The ROP screening criteria used varied within every 
network with the exception of Sweden, where a single 
recommendation was followed. Screening criteria, ideal-
ly, should be based on national or regional epidemiology, 
such as the ongoing active surveillance provided by 
SWEDROP [27]. It is possible that some variations in 
screening criteria reflect local epidemiology, but a review 
of national guidelines may also be warranted. 
Digital retinal photography by trained nonopthalmol-
ogists has the advantage of decreasing the time burden on 
ophthalmologists and provides a permanent record of the 
retinal findings. There is some evidence that remote read-
ing of digital images has good sensitivity for referral-war-
ranted ROP, requiring an examination by an ophthalmol-
ogist [28], and it is likely that this approach will be more 
widely used in the future.
We identified that 29% of NICUs stated they were us-
ing CRYO-ROP criteria despite the benefits of earlier 
treatment [10]. A sub-sample of ANZNN NICUs was re-
surveyed on this question, and all respondents (90% of 
those surveyed) indicated that they used ET-ROP type 1 
criteria, some acknowledging having previously misread 
the question. Even though the criteria were clearly de-
fined in the original questionnaire, the term “threshold” 
(and variants such as pre-threshold) is used loosely in the 
literature and can be misleading. It is possible that re-
sponses to this question from other networks were simi-
larly affected; therefore, it is hard to draw conclusions 
from this part of the survey without resurveying all 
NICUs, which was not practical. Anti-VEGF therapy was 
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used in some NICUs across all networks, but we did not 
survey specific indications for its use, or whether initial 
or rescue therapy was used.
The strengths of our survey include a large, multina-
tional engagement with a high response rate. We cap-
tured contemporary practice and the changing nature of 
practice in response to new evidence. A limitation was 
that the survey was completed by a single individual at 
each site but we did seek NICU policies rather than opin-
ions, so this should not be a source of bias. Ambiguity in 
questionnaires is always a concern. We trialled the survey 
questions amongst iNeo authors, and no problems were 
identified with the ROP treatment criteria question, but 
some of the actual survey respondents appeared to mis-
understand the question. As part of a larger survey, we 
had to limit the number of questions related to ROP, and 
others, including SpO2-monitor alarm settings, could be 
considered in future surveys. We did not link the survey 
results to actual outcomes, which will be the next research 
project for our iNeo collaboration. In addition, we envi-
sion that these data will inform quality improvement ini-
tiatives across each network.
In conclusion, we have identified considerable varia-
tion in SpO2 targets, both within networks and between 
countries, despite recent changes by many NICUs to 
adopt higher SpO2 targets, with the upper limit most fre-
quently set at 94–95%, the lower limit at 90%, and a trend 
to narrower SpO2 targets. In 2015, fewer NICUs than pre-
viously targeted SpO2 limits > 95% or < 85%. Ongoing col-
laborative research is needed to identify and monitor the 
effects of changing neonatal practices and optimize out-
comes for very preterm infants.
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